I think there are two key long-term catalysts for PBTH going forward. The first catalyst is going to be the continued development its therapeutic proteins and more specifically the development of its Carboxyl Terminal Peptide technologies and how those technologies can apply to a larger portfolio of previously-approved proteins in the future. The second catalyst in terms of PBTH is going to be the company's total-debt to total-cash ratio and how that ratio outpaces some of the company's industry based counterparts. Over the last 12 months PBTH has managed to demonstrate a total debt to total cash ratio of 0.00, due largely in part to the fact the company hasn't had any debt over the last 12 months, whereas biotech companies such as Ariad Pharmaceuticals (ARIA) and Nektar Therapeutics (NKTR) carry total debt to total cash ratios of 0.045 and 0.527, respectively.
http://seekingalpha.com/article/837721-2-healthcare-companies-with-new-analyst-coverage-growth-investors-should-consider?source=yahoo
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM